Core Viewpoint - The article discusses the IPO application of Aiko Medical Devices (Beijing) Co., Ltd., which has been accepted by the Shanghai Stock Exchange, aiming to raise 1.1 billion yuan. This marks the company's second attempt after withdrawing its initial application in April 2024. The focus is on the transition from a loss-making state to initial profitability, reflecting the commercialization path of domestic neurointerventional devices [2][14]. Group 1: Product and Market Position - Aiko Medical currently relies heavily on its core product, the Flow Diverter Stent, which accounted for over 95% of its revenue in the first three quarters of 2025, with catheter products making up less than 5% [4]. - The Lattice® series Flow Diverter Stent is primarily used for treating intracranial aneurysms and has a broad range of indications, making it one of the most versatile products in the domestic market [6]. - The company is expanding its product line towards a "full surgical process" approach, transitioning from a single treatment device to a platform of products, which is essential for establishing long-term relationships with hospitals [8][12]. Group 2: Financial Performance and Growth - Aiko Medical's financial situation has improved significantly, with projected revenue of approximately 199 million yuan in 2024 and around 188 million yuan in the first three quarters of 2025. The company has transitioned from substantial losses to a profit stage, driven by the rapid commercialization of its flagship product [16]. - The company reported a net profit of approximately 36.39 million yuan in the first three quarters of 2025, with a net profit margin of about 20%, indicating a healthy cost structure despite the pressures from volume-based procurement [17]. Group 3: Industry Dynamics and Future Outlook - The IPO of Aiko Medical is seen as a reflection of the new phase in the domestic neurointerventional industry, where competition is shifting towards more complex system capabilities and commercialization abilities [18]. - The market for neurointerventional devices is characterized by high technical barriers, strong import dependence, and rigid demand driven by an aging population, suggesting a relatively stable market space [18]. - The combination of volume-based procurement and DRG reforms necessitates a shift in the profitability model for neurointerventional consumables, emphasizing the need for refined cost control and product strategy [18].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 Peijia Medical Limited 沛嘉醫療有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股 份 代 號：9996） 自願性公告 截至2025年12月31日止年度的未經審核營運數據 本公告由沛嘉醫療有限公司（「本公司」，連同其附屬公司統稱「本集團」）自願 刊發，以向本公司股東及潛在投資者提供有關本集團最新業務及產品開發進 展的最新資料。 本公司董事（「董事」）會（「董事會」）欣然宣佈本集團截至2025年12月31日止年度 （「報告期間」）的若干未經審核營運數據及比較數據載列如下。 1月1日至12月31日期間 | 2025年 | 2024年 | 變動 | | --- | --- | --- | | 人民幣百萬元 | 人民幣百萬元 | % | – 1 – 神經介入所有三大產品線均錄得穩健的收入增長，反映其各自核心產品的強 勁表現。主要驅動因素概述如下： 於報告期間，本 ...

Group 1 - The core viewpoint of the article is that Sanofi Bio (300298.SZ) is currently focused on developing its self-researched biosensing technology primarily for monitoring and managing diabetes and related chronic diseases [1] - The company has not yet ventured into the fields of neurointervention or brain-machine interfaces [1] - There are no ongoing preclinical studies specifically targeting neurochemical monitoring [1]

Core Viewpoint - Sanofi Bio (300298.SZ) is currently focused on self-developed biosensing technology primarily for monitoring and managing diabetes and related chronic diseases, with no involvement in neurointervention or brain-computer interface fields, nor has it conducted preclinical research specifically for neurobiochemical monitoring [1] Group 1 - The company is engaged in the development of biosensing technology [1] - The primary application of this technology is in diabetes and related chronic disease management [1] - There is no current involvement in neurointervention or brain-computer interface sectors [1]

Core Viewpoint - The profitability of Xinwei Medical is becoming increasingly clear, with a significant growth forecast for 2025, marking its entry into the profit zone, alongside the acceptance of its innovative self-expanding intracranial drug-eluting stent application by the National Medical Products Administration [1][4]. Financial Performance - Xinwei Medical's 2025 revenue is projected to be between 400 million to 410 million yuan, representing an approximate 44% increase from 278 million yuan in 2024 [6]. - The company expects a pre-tax profit of 80 million yuan, a substantial turnaround from a pre-tax net loss of 12 million yuan in 2024, indicating an increase of nearly 800% [6]. Product Development and Market Position - The growth is primarily driven by the collaborative expansion of the entire product line, particularly in the ischemic stroke sector, where new products and technologies have led to a steady increase in market share [7]. - The sales volume of large-caliber aspiration catheters has seen a 60% year-on-year increase in the first half of 2025, with expectations of over 200% growth for the year [8]. - The "Great Wall" intracranial stent has achieved rapid commercial sales, covering 200 new cooperative hospitals in the first half of the year, significantly boosting the sales of related products [8]. Cost Management and Operational Efficiency - Xinwei Medical's overall gross margin rose to nearly 70% in the first half of 2025, while the sales and management expense ratio decreased by 8 percentage points to 37%, showcasing effective cost control [9]. - The financial characteristics of revenue growth, profit increase, and cost reduction indicate a shift from reliance on financing cash flow to a self-sustaining growth model [9]. Innovation and Long-term Strategy - The acceptance of the self-expanding intracranial drug-eluting stent application highlights the company's leading position in innovation, addressing critical treatment needs in the market [12]. - Xinwei Medical has developed a comprehensive product pipeline for stroke treatment and prevention, including devices for thrombectomy, aneurysm, and stenosis, with several products receiving "priority review" status [12]. - The company is also exploring advanced fields such as the interventional brain-machine interface project, which is expected to begin clinical trials by the end of 2026, potentially expanding its growth horizons [12]. Conclusion - Xinwei Medical's solid profitability, comprehensive product pipeline, leading innovation capabilities, and clear ecological layout constitute its core competitive advantages, gradually gaining market recognition for its investment value [14]. - Short-term growth will be supported by full product line expansion and cost control optimization, while long-term prospects are bolstered by innovative products and strategic positioning in emerging fields [14].

Core Viewpoint - The profitability of Xinwei Medical is becoming increasingly clear, with a significant leap in revenue and profit projected for 2025, marking its entry into the profit zone [1][4]. Financial Performance - Xinwei Medical forecasts a revenue of approximately 400 million to 410 million yuan for 2025, representing a growth of about 44% compared to 278 million yuan in 2024 [6]. - The company expects a pre-tax profit of 80 million yuan, a substantial turnaround from a pre-tax net loss of 12 million yuan in 2024, indicating an increase of nearly 800% [6]. - Adjusted pre-tax profit is projected to reach 77 million yuan, showcasing a clear improvement in profitability quality and capability [6]. Product and Market Development - The growth is primarily driven by the collaborative expansion of the entire product line, particularly in the ischemic stroke sector, where new products and technologies have led to a steady increase in market share [7]. - The sales volume of large-caliber suction catheters has seen a 60% year-on-year increase in the first half of 2025, with an expected annual sales growth of over 200% [7]. - In the hemorrhagic stroke sector, the "Great Wall" intracranial stent has achieved rapid commercial sales, covering 200 new cooperative hospitals in the first half of the year, significantly boosting the sales of spring coil products [8]. Cost Management and Operational Efficiency - Xinwei Medical's overall gross margin has rebounded to nearly 70%, while the sales and management expense ratio has decreased by 8 percentage points to 37%, indicating effective cost control [9]. - The financial characteristics of revenue growth, profit increase, and cost reduction suggest that the company has moved away from a financing-dependent growth model to a self-sustaining cycle of product expansion and profitability [9]. Innovation and Long-term Strategy - The acceptance of the self-expanding intracranial drug-eluting stent application by the National Medical Products Administration represents a significant breakthrough in the company's innovation pipeline [11]. - This product addresses critical treatment needs for intracranial atherosclerotic stenosis and is expected to fill a market gap, enhancing the company's competitive edge in neurointervention [11]. - The company is also advancing its brain-machine interface project, which is expected to begin formal clinical trials by the end of 2026, potentially opening new growth avenues [12]. Conclusion - Xinwei Medical's solid profitability, comprehensive product pipeline, leading innovation capabilities, and clear ecological layout constitute its core competitive advantages, gradually gaining market recognition for its investment value [14]. - Short-term growth will be supported by full product line expansion and cost management optimization, while long-term prospects will be bolstered by innovative products and strategic positioning in emerging fields [14].

Core Viewpoint - Peijia Medical-B (09996) has seen a significant increase in stock price, attributed to the chairman's confidence demonstrated through share buybacks and the recent approval of its TaurusTrio device for market entry [1][2] Group 1: Company Developments - Peijia Medical's stock rose over 6%, with a cumulative increase of over 22% in December [1] - The chairman, Dr. Zhang Yi, plans to invest up to 15 million HKD in purchasing company shares from the open market [1] - The TaurusTrio transcatheter aortic valve system has received approval from the National Medical Products Administration, marking it as the first integrated positioning key transcatheter aortic valve regurgitation intervention device approved in China [1] Group 2: Industry Position - According to CITIC Securities, Peijia Medical holds a leading position in the domestic heart valve intervention market, with positive clinical feedback and increasing market share for its TAVR products since commercialization [2] - The company has a comprehensive product development layout in aortic, mitral, and tricuspid valve treatment areas, which helps solidify its leading position in the heart valve sector [2] - Peijia Medical anticipates the approval and commercialization of three major products by the end of 2025 to 2026, which is expected to drive a rapid recovery in overall performance [2] - The company's neurointerventional business is among the top domestic players, with a promising growth trend expected as the product pipeline continues to expand and commercialization progresses [2]

Core Viewpoint - Peijia Medical (09996) has seen a significant increase in its stock price, rising over 22% in December, with a current price of 6.35 HKD and a trading volume of 10.9 million HKD [1] Group 1: Company Developments - On December 5, Peijia Medical announced that Chairman Dr. Zhang Yi plans to invest up to 15 million HKD to buy back company shares in the open market [1] - On December 11, Peijia Medical received approval from the National Medical Products Administration for its TaurusTrio transcatheter aortic valve system, marking it as the first integrated positioning key transcatheter aortic valve regurgitation (AR) intervention device approved in China [1] Group 2: Market Position and Future Outlook - According to a report from CITIC Securities, Peijia Medical holds a leading position in the domestic heart valve intervention market, with positive clinical feedback and rapid market share growth since the commercialization of its TAVR products [1] - The company has a comprehensive product development pipeline in the aortic, mitral, and tricuspid valve treatment areas, which is expected to strengthen its leading position in the heart valve sector [1] - Peijia Medical anticipates the approval and commercialization of three major products in China by the end of 2025 to 2026, which will support a rapid recovery in overall performance [1] - The company's neurointerventional business is among the top domestic players, and with a continuously enriching product pipeline and ongoing commercialization of certified products, it is expected to maintain a trend of rapid development [1]

Company Overview - Infinity Neuro, a medical device company focused on innovative solutions for neurovascular surgery, has completed a Series A financing round of several hundred million RMB, led by Gaotejia with participation from multiple institutions [1] - The company specializes in the research, production, and commercialization of medical devices in the cerebrovascular field, addressing unmet clinical needs in neurointervention [1] Product Development - The core product, HUB navigation-assisted reperfusion system, is a global first and has significantly reduced the thrombectomy time in traditional interventional surgeries to around 10 minutes, marking a breakthrough in the field of ischemic stroke intervention [2] - The first product, Inspira aspiration catheter, received CE certification under the new EU MDR regulations in January 2023 and is the first neurovascular device approved in Europe under these new rules [2] Market Strategy - Infinity Neuro aims to accelerate the clinical research and global commercialization of its core product through the recent financing, focusing on a dual-engine strategy of globalization and branding [2] - The company has established sales channels in various countries including China, the USA, Western Europe, India, and Brazil, leveraging a global perspective to create differentiated competitive advantages [2] Investment Insights - Investors see significant opportunities in the neurointervention sector, with the potential for domestic replacement and international expansion, as Infinity Neuro is one of the few teams with an international background [2] - The company’s innovative product lineup, developed around clinical pain points, is expected to provide substantial clinical value and address the growing clinical demand driven by an aging population and improved living standards [2]

Core Viewpoint - Guichuang Tongqiao (02190) has seen a stock price increase of over 3%, currently trading at 25.52 HKD, following the approval of its intracranial aneurysm embolization assistive stent by the National Medical Products Administration (NMPA) [1] Group 1: Product Approval and Features - The Tongqiao Feilong intracranial aneurysm embolization assistive stent has received NMPA approval for market launch [1] - This stent is designed to be used in conjunction with embolization coils, specifically targeting the treatment of intracranial neurovascular diseases, providing a new and efficient clinical solution [1] - Compared to similar products on the market, the Tongqiao Feilong stent offers better wall adherence and visibility during procedures, enhancing operational safety and visibility [1] Group 2: Market Impact and Company Strategy - CITIC Securities (601066) highlights that the stent utilizes DFT material weaving technology, which allows for clear visibility throughout the procedure, aiding doctors in precise operational control [1] - The approval of the embolization assistive stent is expected to strengthen the company's product pipeline in the neurointerventional field, enhancing its overall solution offerings [1] - This development is anticipated to help the company increase its market share and maintain rapid growth in performance [1]